Showing results (21-30 of 44) with videos related to
Sort By:
Pageof 5
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617Justin Ferdinandus, John Violet, Shahneen Sandhu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2021
Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial AnalysisLukas Kessler, Justin Ferdinandus, Nader Hirmas, et al.EJNMMI Physics|April 13, 2026
Contrast-enhanced CT for attenuation correction in ultra-high sensitivity long-axial field-of-view lymphoma PET: amplified quantification problems?Jan-Luca Penner, August Blomgren, Alexander Weissensee, et al.European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 2021
68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational TrialLukas Kessler, Justin Ferdinandus, Nader Hirmas, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2021
68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular CarcinomaNader Hirmas, Catherine Leyh, Miriam Sraieb, et al.Leukemia|October 14, 2022
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trialRobert Seifert, David Kersting, Christoph Rischpler, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJohn Violet, Price Jackson, Justin Ferdinandus, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2021
Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 PatientsJustin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, et al.The Lancet. Oncology|May 13, 2018
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyMichael S Hofman, John Violet, Rodney J Hicks, et al.Pageof 5